Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

Methadone maintenance expands inside federal prisons

Barbara Sibbald
CMAJ November 12, 2002 167 (10) 1154;
Barbara Sibbald
CMAJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

In an attempt to curb rising HIV and hepatitis C infection rates and to lower recidivism rates, federal prisons have begun offering methadone maintenance treatment (MMT) to any prisoner with an opiate addiction.

Figure

Figure. Millhaven meltdown: inmates demanding their Charter rights at federal prison Photo by: Canapress

The Correctional Service of Canada (CSC) expanded access to MMT in federal prisons May 2. It estimates that up to 800 prisoners may enter the program within 3 years at an annual cost of more than $10 000 each, or a potential annual total of roughly $8 million.

The new program builds on a 1998 initiative that allowed federal prisoners to continue receiving methadone if they had been in an MMT program in the community before their arrest. In March 1999 the program was temporarily modified to allow, under exceptional circumstances, MMT for severely addicted offenders. As of December 2001, 304 federal prisoners were receiving MMT through these programs, but there was no money for expansion. Of that total, 230 inmates had been receiving methadone in the community prior to their arrest. Another 74 inmates had started receiving it in 2001 under the “exceptional circumstances” provision, 47 of them in the Pacific region.

The problem, says Dr. Françoise Bouchard, CSC's director general, health services, is that the application of “exceptional circumstances” differed across the country. “It was up to individual judgements. We decided to make it more concrete.”

The new program was announced shortly after inmate Barry Strykiwsky settled his court case alleging that Ottawa had violated his Charter rights by not providing him with MMT, a treatment available to other Canadians addicted to heroin. Strykiwsky asked prison officials for MMT in 1998. Even though he had the support of his physician, he was refused.

“I'm encouraged by the new program,” said the head of the Canadian HIV/AIDS Legal Network, Ralf Jürgens, “but I'm dismayed that they waited until the case went to court.”

Bouchard says the CSC was already moving in this direction, but “we needed to measure the impact of [the initial] program.” A CSC study of the impact of the original MMT program found that after a year, 41% of inmates who were receiving MMT were readmitted to prison, compared with 58% of addicted inmates who were not on the program. In a study of 636 former inmates, injection drug users reported significantly more needle sharing (72.6% vs. 51.8%) than users who had not been in prison (Can J Infect Dis 2002; 13 [Suppl A] ).

The new program may also slow the spread of HIV and hepatitis C infections. Among those who agreed to be tested, 1.8% were HIV positive at the end of 2002. In 1989, there were 24 known HIV-positive federal inmates; in 2001, there were 223. (At the end of 2001, the rate of hepatitis C infection among federal inmates who have been tested was 23.6%.)

CSC says this “dramatic rise … in the past decade is linked in large measure with the substance-abuse practices and associated lifestyles of many of these offenders” before they arrive in prison.

Despite CSC's “zero tolerance” for drug abuse in prisons, the problem is pervasive. The service estimates that 70% of inmates have drug or alcohol abuse problems when they enter prison. “It's logical that they would try to sustain [their habit] while in here,” says Bouchard. “This [MMT] is not only a harm-reduction measure, but it is designed to stop drug substance abuse. It's the only effective medical treatment for opiate drug users.”

According to a CSC study, 80% of inmates have abused alcohol or drugs and 34% used injection drugs prior to their incarceration; 11% reported using them while in custody, and 25% said they were under pressure to smuggle drugs into the institution.

Jürgens is pushing for needle-exchange programs in prisons — he says they have proven effective in Europe and do not increase drug use or threats to staff. “There's clearly a need for the federal prison system to do a pilot study.”

Needle-exchange programs as a harm-reduction measure are being considered, says Bouchard, but their implementation is not imminent.

Provincial prisons

Addicted inmates at provincial prisons (where sentences under 2 years are served) have fewer harm-reduction options. Inmates who were in an MMT program outside prison are eligible for in-prison treatment (if available) in all provinces except PEI and Newfoundland. No provinces offer it to addicted inmates who were not previously on a program. — Barbara Sibbald, CMAJ

PreviousNext
Back to top

In this issue

CMAJ
Vol. 167, Issue 10
12 Nov 2002
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Methadone maintenance expands inside federal prisons
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Methadone maintenance expands inside federal prisons
Barbara Sibbald
CMAJ Nov 2002, 167 (10) 1154;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Methadone maintenance expands inside federal prisons
Barbara Sibbald
CMAJ Nov 2002, 167 (10) 1154;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Prescribing Opioid Replacement Therapy in U.S. Correctional Settings
  • Google Scholar

More in this TOC Section

  • Saying goodbye to CMAJ News
  • National survey highlights worsening primary care access
  • How Canadian hospitals are decreasing carbon emissions
Show more News

Similar Articles

Collections

  • Topics
    • Addiction medicine
    • Prison medicine

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire